Helen Varker

1.3k total citations · 1 hit paper
36 papers, 1.0k citations indexed

About

Helen Varker is a scholar working on Hematology, Genetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Helen Varker has authored 36 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 7 papers in Genetics and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Helen Varker's work include Hemoglobinopathies and Related Disorders (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Atrial Fibrillation Management and Outcomes (5 papers). Helen Varker is often cited by papers focused on Hemoglobinopathies and Related Disorders (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Atrial Fibrillation Management and Outcomes (5 papers). Helen Varker collaborates with scholars based in United States, United Kingdom and Germany. Helen Varker's co-authors include Jay Lin, Gerald V. Naccarelli, Kathy L. Schulman, Alpesh Amin, Stephen S. Johnston, Stephen Thompson, Nicole Princic, Xue Song, Kathleen Wilson and Stephen Sander and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The American Journal of Cardiology.

In The Last Decade

Helen Varker

35 papers receiving 979 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increasing Prevalence of Atrial Fibrillation and Flutter in the United States

2009 646 citations Gerald V. Naccarelli, Helen Varker et al. The American Journal of Cardiology profile →

Peers

Countries citing papers authored by Helen Varker

Since Specialization

Citations

This map shows the geographic impact of Helen Varker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Varker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Varker more than expected).

Fields of papers citing papers by Helen Varker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Varker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Varker. The network helps show where Helen Varker may publish in the future.

Co-authorship network of co-authors of Helen Varker

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Varker. A scholar is included among the top collaborators of Helen Varker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Varker. Helen Varker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EE149 Economic Burden of Treating Chronic Peripheral Neuropathic Pain in the United States: National Estimates From 2022 Data 2024 ·Value in Health ·(unknown), James D. Geiger, Nicole Princic, (unknown), Helen Varker, Zhen Wang, Lei Shi, Marjorie Stiegler, (unknown)	1
2	Development of a claims-based flare algorithm for systemic lupus erythematosus 2022 ·Current Medical Research and Opinion ·Iris Goetz, Casey Choong, (unknown), David R. Nelson, Julie Birt, Virginia Noxon, Helen Varker, Nicole M. Zimmerman, Joseph Tkacz	3
3	PRO35 ECONOMIC BURDEN OF CHRONIC RED BLOOD CELL TRANSFUSIONS AMONG PATIENTS WITH SICKLE CELL DISEASE 2020 ·Value in Health ·Ram Kalpatthi, Xiaoming Song, (unknown), (unknown), Helen Varker, (unknown), (unknown)	2
4	Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema 2020 ·Journal of Managed Care & Specialty Pharmacy ·Szilárd Kiss, (unknown), Kathleen Wilson, Helen Varker, (unknown), David M. Smith, (unknown)	16
5	Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy 2017 ·Clinical Colorectal Cancer ·Stephen S. Johnston, Kathleen Wilson, Helen Varker, (unknown), Paul Juneau, Ellen Riehle, Sacha Satram‐Hoang, Nicolas Sommer, Sarika Ogale	9
6	Difference in intraocular pressure following involuntary switch from bimatoprost 0.03% to bimatoprost 0.01% in glaucoma patients. 2016 ·Investigative Ophthalmology & Visual Science ·Carlos Quezada-Ruiz, (unknown), Kathleen Wilson, (unknown), David M. Smith, Helen Varker, Stephen S. Johnston	1
7	Real-world treatment patterns in injection cost and frequency for ranibizumab versus aflibercept in patients with wet age-related macular degeneration: A 2-year US claims analysis 2016 ·Investigative Ophthalmology & Visual Science ·Szilárd Kiss, (unknown), Carlos Quezada-Ruiz, Kathleen Wilson, (unknown), David M. Smith, Helen Varker, Stephen S. Johnston	2
8	Comparison Of Treatment-Related Adverse Events Recorded In Administrative Claims Data With Those Recorded In Electronic Medical Records For Multiple Myeloma Patients 2015 ·Value in Health ·(unknown), Helen Varker, (unknown)	1
9	Injection frequency and costs of Anti-Vegf treatments for Neovascular age-related Macular Degeneration, Retinal Vein Occlusion, and Diabetic Macular Edema 2015 ·Value in Health ·Adam Turpcu, Kathleen Wilson, (unknown), David M. Smith, Helen Varker, Stephen S. Johnston	1
10	Development and validation of a u.s. Administrative claims-based algorithm to classify patients with type 2 diabetes mellitus into renal impairment stages 2015 ·Value in Health ·Stephen S. Johnston, John J. Sheehan, Ellen Riehle, Katherine Cappell, Helen Varker, Deborah Anzalone, (unknown), (unknown)	2
11	Treatment Patterns and Associated Costs of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration 2014 ·Investigative Ophthalmology & Visual Science ·Szilárd Kiss, Pravin U. Dugel, Kathleen Wilson, (unknown), David M. Smith, Helen Varker, Stephen S. Johnston, Adam Turpcu	2
12	Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels 2014 ·BMC Nephrology ·Katherine Cappell, Sanatan Shreay, Zhun Cao, Helen Varker, Carly J. Paoli, Matthew Gitlin	17
13	Assessing The Impact Of Patient-Reported Outcomes And Health Economic Benefit Claims On The Market Value Of Oncologic Pharmaceuticals 2013 ·Value in Health ·Jeffrey D. Miller, (unknown), (unknown), Kathleen A. Foley, Helen Varker, Gregory Lenhart	1
14	Retrospective Analysis of First-Line Anti-Vascular Endothelial Growth Factor Treatment Patterns in Wet Age-Related Macular Degeneration 2013 ·Advances in Therapy ·Stephen S. Johnston, Kathleen Wilson, (unknown), David M. Smith, Helen Varker, Adam Turpcu	33
15	Treatment patterns among cancer patients with anemia who do not respond to erythropoietin-stimulating agents. 2013 ·Journal of Clinical Oncology ·Allicia C. Girvan, Yiu-Keung Lau, Lee Bowman, Gerhardt Pohl, Pamela Landsman‐Blumberg, Nianwen Shi, Helen Varker	1
16	Patterns and Predictors of Use of Warfarin and Other Common Long-Term Medications in Patients with Atrial Fibrillation 2012 ·American Journal of Cardiovascular Drugs ·Xue Song, Stephen Sander, Helen Varker, Alpesh Amin	23
17	Outpatient red blood cell transfusion payments among patients on chronic dialysis 2012 ·BMC Nephrology ·Matthew Gitlin, (unknown), David M. Spiegel, Jeffrey L. Carson, Xue Song, Brian Custer, Zhun Cao, Katherine Cappell, Helen Varker, Shaowei Wan, Akhtar Ashfaq	7
18	Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes 2011 ·Lung Cancer ·Xue Song, Helen Varker, Michel Eichelbaum, Peter Stopfer, Mehdi Shahidi, Kathleen Wilson, R. Kaiser, Henrik W. Finnern	11
19	Cost burden of second fracture in the US Health System 2011 ·Bone ·Xue Song, Nianwen Shi, Enkhe Badamgarav, Joel Kallich, Helen Varker, Gregory Lenhart, (unknown)	39
20	Increasing Prevalence of Atrial Fibrillation and Flutter in the United States breakdown → 2009 ·The American Journal of Cardiology ·Gerald V. Naccarelli, Helen Varker, Jay Lin, Kathy L. Schulman	646

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact